PICC-port
DeviceImplantation of a PICC-port device by a dedicated PICC team member following predefined evidence-based international guidelines and protocols
NCT Number: NCT06541301
Central venous access devices are extensively used in oncology patients. The current standard is represented by devices inserted by direct ultrasound guided cannulation of deep veins of supra/infraclavicular area with a reservoir placed in a subcutaneous pocket of the upper chest wall ("chest-ports"). More recently, PICC (Peripherally Inserted Central Catheters)-ports have been proposed as an alternative to chest-ports.
Aim of this study is to demonstrate the non-inferiority of PICC ports compared to thoracic ports in terms of efficacy and safety.
Trial opening soon.
Get Notified18 year–75 year
All sexes
Interventional
Not applicable
CRO (Centro di Riferimento Oncologico), Aviano, Italy
Central venous access devices are extensively used in oncology patients who need safe deliverance of chemotherapeutic agents and drugs, transfusion of blood and blood products, and performance of laboratory tests, in solid as well as hematologic malignancies. These devices are mostly inserted by direct ultrasound guided cannulation of deep veins of supra/infraclavicular area and the reservoir is placed in a subcutaneous pocket of the upper chest wall ("chest-ports"). More recently, PICC (Peripherally Inserted Central Catheters)-ports have been proposed as a safe and effective alternative to chest-ports, claiming lower invasiveness, easier insertion and better patients' compliance. In PICC-ports a small reservoir is placed in a subcutaneous pocket located in the mid-third of the upper arm.
Since these feelings are currently based only on limited retrospective studies, aim of this randomized multicenter trial is to demonstrate the non-inferiority of PICC ports (experimental arm) compared to thoracic ports (control arm, as the current reference standard) in terms of efficacy and safety.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Implantation of a PICC-port device by a dedicated PICC team member following predefined evidence-based international guidelines and protocols
Implantation of a Chest-port device by expert physicians or certified expert nurses, following predefined evidence-based international guidelines and protocols
Time frame: 6 months
Number of unscheduled removal of the device due to complications
Time frame: 6 months
Number of adverse events associated with the implantation and use of the device that do not necessitate its removal
Contact information is provided by the study sponsor or research team.
European Institute of Oncology
Other
PICC-ports Versus Chest - Ports for Long Term Chemotherapy Deliverance in Oncology Patients Affected by Solid Tumors. A Prospective, Randomized Multicentric, Non Inferiority, Phase III Trial.
Acronym: PICCHEST
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07739966
Bronchial Neoplasms, Carcinoma, Bronchogenic
View Trial DetailsNCT07676903
Solid Tumor
Beijing, Beijing Municipality, China
View Trial DetailsNCT07715747
Adnexal Diseases, Digestive System Diseases
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07678970
Digestive System Diseases, Digestive System Neoplasms
Harbin, Heilongjiang, China
View Trial Details